In vivo characterization of novel full and partial 2-(4-aminophenyl)-N, N-dipropylethylamine dopamine D2 receptor agonists

European Journal of Pharmacology

Volumn 394, Issue 2-3, 2000, Pages 247-253

  Ahlenius, Sven ^a   Ericson, Evalena ^a   Florvall, Lennart ^a   Jiménez, Patricia ^a   Hillegaart, Viveka ^a   Wijkström, Agneta ^a  

^a Astra Arcus AB   (Sweden)

Author keywords

Dopamine D2 receptor; Dopamine synthesis; Locomotor activity; Partial agonist; Rat

Indexed keywords

2 (4 AMINO 3 BROMO 5 TRIFLUOROMETHYLPHENYL) N,N DIPROPYLETHYLAMINE; 2 (4 AMINO 3 TRIFLUOROMETHYLPHENYL) N,N DIPROPYLETHYLAMINE; 2 (4 AMINOPHENYL) N,N DIPROPYLETHYLAMINE; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 3 O METHYLDOPAMINE; APOMORPHINE; BROCRESINE; DEXAMPHETAMINE; DOPA; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; GAMMA BUTYROLACTONE; HALOPERIDOL; METIROSINE METHYL ESTER; NBF 203; NBF 234; PARGYLINE; PARTIAL AGONIST; RESERPINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINE RELEASE; DRUG ANTAGONISM; FOREBRAIN; LOCOMOTION; MALE; NEOCORTEX; NEOSTRIATUM; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR INTRINSIC ACTIVITY; TURNOVER TIME;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; 4-BUTYROLACTONE; ALPHA-METHYLTYROSINE; ANIMALS; BRAIN CHEMISTRY; CATECHOLAMINES; DIHYDROXYPHENYLALANINE; DOPAMINE; DOPAMINE AGONISTS; ETHYLAMINES; FLUOROBENZENES; GABA MODULATORS; MALE; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; PARGYLINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RESERPINE; SYMPATHOLYTICS;

EID: 0034646977     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00158-8     Document Type: Article

References (35)

1. Ahlenius S. Effects of the local application of 3-PPP and sulpiride enantiomers into the nucleus accumbens or into the ventral tegmental area on rat locomotor activity: evidence for the functional importance of somato-dendritic autoreceptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 345:1992;516-522.
2. Andén N.-E. Regulation of monoamine synthesis and utilization by receptors. Handb. Exp. Ther. 54:1980;429-462.
3. Andén N.-E., Golembiowska-Nikitin K., Thornström U. Selective stimulation of dopamine and noradrenaline autoreceptors by B-HT 920 and B-HT 933, respectively. Naunyn-Schmiedeberg's Arch. Pharmacol. 321:1982;100-104.
4. Benkert O., Muller-Siecheneder F., Wetzel H. Dopamine agonists in schizophrenia. Eur. Neuropsychopharmacol. 5:1995;43-53.
5. Bunney B.S., Sesack S.R., Silva N.L. Midbrain dopaminergic systems: neurophysiology and electrophysiological pharmacology. Meltzer H.Y. Psychopharmacology: The Third Generation of Progress. 1987;113-126 Raven Press, New York.
6. Carlsson A. Overview of dopamine mechanisms: neurochemical and pharmacological evidence. Helmchen H., Henn F.A. Biological Perspectives of Schizophrenia. 1987;283-297 Wiley, Chichester.
7. Clark D., Hjorth S., Carlsson A. Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity: I. Review of the evidence. J. Neural Transm. 62:1985;1-52.
8. Clark D., Hjorth S., Carlsson A. Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity: II. Theoretical considerations. J. Neural Transm. 62:1985;171-207.
9. Eilam D., Szechtman H. Biphasic effect of D-2 agonist quinpirole on locomotion and movements. Eur. J. Pharmacol. 161:1989;151-157.
10. Ericson E., Samuelsson J.,. Ahlenius S. Photocell measurements of rat motor activity. J. Pharmacol. Methods. 25:1991;111-122.
11. Florvall L., Hillegaart V., Malmberg Å., Wijkström A., Ahlenius S. Partial dopamine receptor agonists with different degrees of intrinsic activity within a series of 2-(4-aminophenyl)-N, N-dipropylethylamine derivatives: synthetic chemistry and structure-activity relationships. Eur. J. Med. Chem. 31:1996;133-142.
12. Hagan J.J., Middlemiss D.N., Sharpe P.C., Poste G.H. Parkinson's disease: prospects for improved drug therapy. Trends Pharmacol. Sci. 18:1997;156-163.
13. Hillegaart V., Hjorth S., Ahlenius S. Effects of 5-HT and 8-OH-DPAT on forebrain monoamine synthesis after local application into the median and dorsal raphe nuclei of the rat. J. Neural Transm. 81:1990;131-145.
14. Hjorth S., Clark D., Svensson K., Carlsson A., Thorberg O. Sub-chronic administration of (-)-3-PPP and central dopamine receptor sensitivity changes. J. Neural Transm. 64:1985;187-198.
15. Hoyer D., Boddeke H.W.G.M. Partial agonists, full agonists, antagonists: dilemmas of definition. Trends Pharmacol. Sci. 14:1993;270-275.
16. Jackson D., Carlsson A., Hjorth S., Lindberg P. A behavioural study of the changes in the central nervous system of mice after subchronic treatment with the selective dopamine autoreceptor agonist 3-PPP (D, L-3[3-hydroxyphenyl]-N-n-propylpiperidine). J. Neural Transm. 53:1982;233-245.
17. Kehr W. Transdihydrolisuride, a partial dopamine receptor antagonist: effects on monoamine metabolism. Eur. J. Pharmacol. 97:1984;111-119.
18. Lahti A., Weiler M.A., Corey P.K., Lahti R.A., Carlsson A., Tamminga C. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia. Biol. Psychiatry. 43:1998;2-11.
19. Lawler C.P., Prioleau C., Lewis M.M., Mak C., Jiang D., Schetz J.A., Gonzalez A.M., Sibley D.R., Mailman R.B. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 20:1999;612-627.
20. Lundström J., Lindgren J.-E., Ahlenius A., Hillegaart V. Relationship between brain levels of 3-(3-hydroxyphenyl)-N-n-propylpiperidine HCl enantiomers and effects on locomotor activity in rats. J. Pharmacol. Exp. Ther. 262:1992;41-47.
21. Magnusson O., Nilsson L.B., Westerlund D. Simultaneous determination of dopamine, DOPAC and homovanillic acid. Direct injection of supernatants from brain tissue homogenates in a liquid chromatography-electrochemical detection system. J. Chromatogr. 221:1980;237-247.
22. Mierau J., Schingnitz G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur. J. Pharmacol. 215:1992;161-170.
23. Mohringe B., Magnusson O., Thorell G., Fowler C.J. Seasonal variations in the stability of monoamines and their metabolites in perchloric acid as measured by high-performance liquid chromatography. J. Chromatogr. 361:1986;291-299.
24. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1998;Academic Press, San Diego.
25. Pizzolato G., Soncrant T.T., Rapoport S.L. Time-course and regional distribution of the metabolic effects of bromocriptine in the rat brain. Brain Res. 341:1985;303-312.
26. Roth R.H. CNS dopamine autoreceptors: distribution, pharmacology, and function. N. Y. Acad. Sci. 430:1984;27-53.
27. Roth R.H., Elsworth J.D. Biochemical pharmacology of midbrain dopamine neurons. Bloom F.E., Kupfer D.J. Psychopharmacology: The Fourth Generation of Progress. 1995;227-243 Raven Press, New York.
28. Seyfried C.A., Greiner H.E., Haase A.F. Biochemical and functional studies on EMD 49980: a potent, selectively presynaptic D-2 dopamine agonist with actions on serotonin systems. Eur. J. Pharmacol. 160:1989;31-41.
29. Strömbom U. Catecholamine receptor agonists: effects on motor activity and rate of tyrosine hydroxylation in mouse brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 292:1976;167-176.
30. Svensson K., Eriksson E., Carlsson A. Partial dopamine receptor agonists reverse behavioral, biochemical and neuroendocrine effects of neuroleptics in the rat: potential treatment of extrapyramidal side effects. Neuropharmacology. 32:1993;1037-1045.
31. Tamminga C., Gotts M.D., Thaker G.K., Alphs L.D., Foster N.L. Dopamine agonist treatment of schizophrenia with N-propyl-norapomorphine. Arch. Gen. Psychiatry. 43:1986;398-402.
32. Waddington J.L., Daly S.A., Downes R.P., Deveney A.M., McCauley P.G., O'Boyle K.M. Behavioural pharmacology of 'D-1-like' dopamine receptors: further subtyping, new pharmacological probes and interactions with 'D-2-like' receptors. Progr. Neuro-Psychopharmacol. Biol. Psychiatry. 19:1995;811-831.
33. Winer B.J. Statistical Principles in Experimental Design. 1971;McGraw-Hill, New York.
34. Wood P.L., Altar C.A. Dopamine release in vivo from nigrostriatal, mesolimbic, and mesocortical neurons: utility of 3-methoxytyramine measurements. Pharmacol. Rev. 40:1988;163-187.
35. 2 receptor antagonist. Life Sci. 42:1988;1941-1954.